Paulex Bio Inc.
Paulex Bio stands at the threshold of what could be a transformative breakthrough for type 1 and type 2 diabetes: beta cell regeneration through an oral medicine designed to eliminate the root cause of diabetes.
Funding history
About Paulex Bio Inc.
How much funding has Paulex Bio Inc. raised?
Paulex Bio Inc. has raised $18.5M in total funding. The most recent round was Series B.
Where is Paulex Bio Inc. headquartered?
Paulex Bio Inc. is headquartered in La Jolla, CA.
What does Paulex Bio Inc. do?
Paulex Bio stands at the threshold of what could be a transformative breakthrough for type 1 and type 2 diabetes: beta cell regeneration through an oral medicine designed to eliminate the root cause of diabetes.
What problem does Paulex Bio Inc. solve?
Type 1 and type 2 diabetes currently lack a treatment that addresses its root cause.
What's Paulex Bio Inc.'s solution?
Paulex Bio is developing an oral medicine intended to regenerate beta cells and eliminate the root cause of diabetes.
What makes Paulex Bio Inc. different?
They frame their approach as targeting beta cell regeneration itself (versus symptom management), describing it as a potential 'functional cure' delivered via an oral medicine.
What makes Paulex Bio Inc. notable?
Co-founded by Miguel Sanjuan and Francisco Leon, who previously built Provention Bio, which was acquired by Sanofi for $2.9 billion.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.